See the DrugPatentWatch profile for Gonadorelin
Gonadorelin has received FDA approval for various indications, and its approved status extends beyond 2026 [1][2]. The drug, a synthetic analog of gonadotropin-releasing hormone (GnRH), is used to treat certain conditions related to sex hormone production [3].
What is Gonadorelin Used For?
Gonadorelin is indicated for the treatment of central precocious puberty, a condition where children begin puberty at an unusually early age [3]. It is also used in diagnostic testing for assessing the pituitary's response to GnRH and in the palliative treatment of advanced prostate cancer, where it helps to reduce testosterone levels [3].
How Does Gonadorelin Work?
Gonadorelin functions by initially stimulating the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland [3]. However, with continuous administration, it leads to a downregulation of GnRH receptors, resulting in decreased LH and FSH secretion and consequently reduced production of sex hormones like testosterone and estrogen [3].
What Formulations of Gonadorelin Are Available?
Gonadorelin is available in injectable formulations [3]. Different brand names may be associated with specific formulations and indications, such as Supprelin-LA for central precocious puberty and Lutrepulse for diagnostic testing [1][2][4].
Are There Any Upcoming FDA Approvals for Gonadorelin?
Information regarding specific upcoming FDA approvals for gonadorelin beyond its current indications or formulations is not publicly detailed in the provided context. The drug has established approved uses and its approval status for these uses continues past 2026 [1][2].
What Are the Side Effects of Gonadorelin?
Potential side effects of gonadorelin treatment can include injection site reactions, such as pain, redness, or swelling [3]. Systemic effects may involve hot flashes, mood changes, and changes in libido, particularly relevant in adult patients [3]. For children treated for precocious puberty, side effects can also relate to the suppression of sex hormone production [3].
How Does Gonadorelin Compare to Other GnRH Agonists?
Gonadorelin is a GnRH analog, similar to other drugs like leuprolide and goserelin, which also work by modulating GnRH receptor activity [3][5]. The primary difference often lies in their specific pharmacokinetic profiles, approved indications, and dosing regimens [3][5]. While gonadorelin can be used for short-term diagnostic stimulation, other GnRH agonists are typically used for long-term suppression of sex hormones [3][5].
What is the Patent Status of Gonadorelin?
The patent landscape for gonadorelin and its formulations is complex and evolving. Exclusivity periods and patent expirations can vary for different formulations and their associated intellectual property [4]. Companies may seek to extend market exclusivity through new patent filings or by developing improved formulations.
Who Manufactures Gonadorelin?
Gonadorelin is manufactured and marketed by several pharmaceutical companies. For instance, Bisio is associated with Supprelin-LA, while Ferring Pharmaceuticals is involved with Lutrepulse [1][2]. Other manufacturers may also produce generic or different branded versions of gonadorelin.
What Are the Regulatory Considerations for Gonadorelin?
The FDA regulates gonadorelin to ensure its safety and efficacy for approved uses [1][2]. This includes requirements for manufacturing standards, labeling, and post-market surveillance. Any new indications or significant changes to existing formulations would require further FDA review and approval.
Sources
1. https://www.supprelin-la.com/
2. https://www.ferring.com/
3. https://www.ncbi.nlm.nih.gov/books/NBK557488/
4. https://www.drugs.com/drug-patent-list.html?drugid=3156
5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532692/